The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: Results from a population-based cohort

Mayo Clinic Proceedings

Volumn 87, Issue 6, 2012, Pages 540-547

  Nabhan, Mohammed ^a   Kim, Simon P ^a   Shah, Nilay D ^a   Bagniewski, Stephanie M ^a   Shi, Qian ^a   Karnes, R Jeffrey ^a   Weight, Christopher J ^a   Davis, Brian J ^a   Kohli, Manish ^a   Tilburt, Jon C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RECURRENCE; BRACHYTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; WATCHFUL WAITING;

EID: 84863446010     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.01.017     Document Type: Conference Paper

References (27)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Horner MJ, Ries LAG, Krapcho M. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2009.
3. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21(11):2163-2172. (Pubitemid 46606365)
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17): 1591-1597. (Pubitemid 29211767)
5. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126-131.
6. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006; 24(1):46-50. (Pubitemid 43097357)
7. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280(11):975-980. (Pubitemid 28445095)
8. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713-2719. (Pubitemid 38725420)
9. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250- 1261. (Pubitemid 351439226)
10. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005; 294(4):440-447. (Pubitemid 41124176)
11. Thompson RH, Blute ML, Slezak JM, Bergstralh EJ, Leibovich BC. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol. 2007;178(2):459-463; discussion 463. (Pubitemid 47030503)
12. Han KR, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol. 2004; 171(3):1117-1121. (Pubitemid 38327539)
13. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005; 23(28):7005-7012.
14. Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974.
15. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol. 2006;24(24):3973-3978. (Pubitemid 46630746)
16. Schellhammer P, Cockett A, Boccon-Gibod L, et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology. 1997;49(4A)(suppl):27-38. (Pubitemid 27157681)
17. Ciezki JP, Reddy CA, Stephenson AJ, et al. The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment. Urology. 2010;75(2):467-471.
18. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010;170(15):1390-1395.
19. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer (Version 03.2010); 2010. National Comprehensive Cancer Network. www.NCCN.org.
20. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clinic Proc. 1996;71(3):266-274.
21. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. (Pubitemid 28445094)
22. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998; 36(1):8-27. (Pubitemid 128456396)
23. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standardin the reporting of surgical outcomes. J Urol. 2007;177(2):540-545. (Pubitemid 46054056)
24. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710-719. (Pubitemid 14202071)
25. Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol. 2010;184(3):925-929.
26. Wallner LP, Sarma AV, Lieber MM, et al. Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: The Olmsted County study. Cancer Epidemiol Biomarkers Prev. 2008; 17(12):3588-3592.
27. Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK. The economic burden of prostate cancer survivorship care. J Urol. 2010;184(2):532-538.